Brief: Verona Pharma To Announce Top-Line Data From Phase 3 Enhance-2 Trial Of Nebulized Ensifentrine For Copd
08/08/2022 23:39
Verona Pharma PLC I9SAy.F :
* VERONA PHARMA TO ANNOUNCE TOP-LINE DATA FROM PHASE 3
ENHANCE-2
TRIAL OF NEBULIZED ENSIFENTRINE FOR COPD
Source text for Eikon: ID:nGNXb9QGCJ
Further company coverage: I9SAy.F
Recent news on Verona Pharma
See all newsBrief: Acquisition Of Verona By Msd Approved By The High Court Of Justice Of England And Wales
Brief: Shareholders Of Verona Pharma Approve Proposed Acquisition By Merck
US corporate debt market returns in force after market holiday
Merck to cut jobs and costs as demand for Gardasil in China remains weak (updated)
Merck to cut jobs and costs as demand for Gardasil in China remains weak